Endologix announced today that 12-month results from a trial of its Detour system demonstrated a low rate of complications.
Irvine, California-based Endologix’s Detour 2 FDA investigational device exemption (IDE) study was designed to evaluate the safety and effectiveness of the Detour system for percutaneous bypass in the treatment of long-segment femoropopliteal disease.
Get the full story at our sister site, Medical Tubing & Extrusion.